Within the EGFR family, HER2 is one of the most important members and when overexpressed, represents one of the most aggressive phenotypes (approximately 20%–25% of invasive breast cancers) [4], making HER2 a well-established therapeutic target. This evidence concerns the gene ERBB2 and invasive breast carcinoma.